ANXA2 is abnormally expressed in a variety of tumors, such as glioma (Ma et al., 2021b), cervical cancer (Wang et al., 2021), LIHC (Yu et al., 2007), triple-negative breast cancer (Gibbs et al., 2020) and nasopharyngeal carcinoma (Chen et al., 2018), and can serve as a prognostic marker in these tumors. Here, ANXA2 is linked to cervical cancer.